{
    "abstract": "Non-small cell lung cancer patients with EGFR mutation have a high rate of brain metastases, and EGFR tyrosine kinase inhibitors (TKIs) are the principal therapeutic approach. However, acquired targeted therapy resistance is the main reason for EGFR-TKIs' treatment failure. At present, the mechanism of intracranial acquired targeted therapy resistance is limited, mainly due to the lack of a cell line that can be used for its study.\nA brain parenchymal metastatic sample that progressed after third-generation EGFR-TKI treatment was used to establish a cell line named AlmoR1. The genetic characteristics of the cell line were evaluated by short tandem repeat (STR) profiling and whole-exome sequencing analysis. The phenotypic characteristics were characterized by CCK8, western blot, HE staining, immunohistochemistry (IHC), and orthotopic brain tumor model.\nThe cell line we successfully established, AlmoR1, can be passed in\u00a0vitro stably. STR analysis revealed it was a novel NSCLC BM cell line. It harbors the EGFR E746_A750del (ex19del) mutation, and the IC50 to almonertinib and osimertinib of AlmoR1 was significantly higher than that of sensitive cells. In our orthotopic brain tumor model construction with AlmoR1 cells, 75% (3/4) tumor formation can be observed in the living system.\nThese data suggest that the established cell line, AlmoR1, preserved the resistance to broad third-generation EGFR-TKIs and good tumorigenicity in an intracranial orthotopic model, so that it can serve as a new tool to elucidate the pathogenesis, explore new treatment methods, and conduct the development of new drugs for targeted therapy resistance of brain metastases.",
    "authors": [
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Jingyi",
            "initials": "J",
            "lastname": "Wu"
        },
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Xiangfei",
            "initials": "X",
            "lastname": "Wu"
        },
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Jing",
            "initials": "J",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Neurosurgery, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Guili",
            "initials": "G",
            "lastname": "Feng"
        },
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Yuhan",
            "initials": "Y",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Interventional Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Zide",
            "initials": "Z",
            "lastname": "Chen"
        },
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Wei",
            "initials": "W",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.",
            "firstname": "Rong",
            "initials": "R",
            "lastname": "Wang"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.",
    "doi": "10.1002/cam4.70827\n10.1007/s10585-013-9566-9\n10.1093/neuonc/nos135",
    "journal": "Cancer medicine",
    "keywords": [
        "AlmoR1",
        "NSCLC",
        "brain metastasis",
        "primary culture",
        "the resistance of third\u2010generation EGFR\u2010TKIs"
    ],
    "methods": null,
    "publication_date": "2025-04-02",
    "pubmed_id": "40172035\n38572751\n38384472\n37592034\n32634610\n38924756\n36863484\n33489821\n39134529\n37015337\n35176458\n35932953\n35305259\n35580297\n31751012\n29151359\n38412397\n35534623\n39116206\n35644609\n36572759\n32923895\n19010923\n30926637\n25581823\n32629177\n31233205\n23322381\n22679124\n31780784\n21487419\n35427766",
    "results": "The cell line we successfully established, AlmoR1, can be passed in\u00a0vitro stably. STR analysis revealed it was a novel NSCLC BM cell line. It harbors the EGFR E746_A750del (ex19del) mutation, and the IC50 to almonertinib and osimertinib of AlmoR1 was significantly higher than that of sensitive cells. In our orthotopic brain tumor model construction with AlmoR1 cells, 75% (3/4) tumor formation can be observed in the living system.",
    "title": "Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR-TKI Resistance.",
    "xml": "<Element 'PubmedArticle' at 0x788503cc0f40>"
}